drugset / Trial / NCT04760743
Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)
RandomizedParallel-groupDouble-blindPrevention
Summary
This study is to assess the safety, reactogenicity and immunogenicity of a SK SARS-CoV-2 recombinant protein subunit vaccine (NBP2001) in healthy adults.
Timeline
- Start
- 2020-12-17
- Primary completion
- 2021-04-02
- Completion
- 2022-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NBP2001 | Vaccine | 30 ug | Intramuscular |
| Subject | NBP2001 | Vaccine | 50 ug | Intramuscular |
Indications
No indication recorded.